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Research background. During the current SARS-CoV2 pandemic, as well as earlier SARS 
and MERS epidemics, it has been observed that COVID19-positive women on average tend 
to have milder symptoms and lower fatality rates than men. There is a number of differ-
ences between the sexes known to contribute to different immune responses and sever-
ity of the disease, one being the effect of estrogen via estrogen receptor signalling. We 
wondered if estrogen might also affect the SARS-CoV2 more directly, perhaps by binding 
to the surface glycoprotein (S protein), thus possibly reducing its infectivity. 
Experimental approach. To assess whether there is a possibility for estrogen binding 
on the SARS-CoV2 S protein, we used BLAST and HHpred to compare protein sequences 
of S protein and human estrogen receptor β, while 3D structures of a potential estrogen 
binding site and an active site of estrogen receptor β were visualized and compared using 
PyMOL. 
Results and conclusions. By comparing the sequence of SARS-CoV2 S protein with the 
human estrogen receptor β, we identified a potential estrogen binding site on S protein 
and further determined that it also shares notable similarities with the active site of ER β 
when observed in 3D structure of their respective proteins. As a control, SARS-CoV2 S pro-
tein was compared with the human androgen receptor, and no such similarities were 
found. The potential estrogen binding site is part of coronavirus S2 superfamily domain, 
which is involved in host-virus membrane fusion during infection and appears to be con-
served throughout the Coronaviridae family. 
Novelty and scientific contribution: This preliminary communication shows that SARS-
-CoV2 S protein features a potential estrogen binding site. Hopefully, this will prompt a 
more comprehensive study on the possibilities of estrogen binding on the S protein and 
the effect this might confer on the virus infectivity. 
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INTRODUCTION
The COVID-19 pandemic that has resulted in high numbers of critically ill patients and 
deaths is caused by novel coronavirus SARS-CoV2. Studies on the infection and clinical 
management reported sex differences in severity and outcome of the COVID-19 disease 
(1–7). It is known that males are more susceptible to influenza and common cold than fe-
males of the same age (8–10). Two other coronaviruses that also cause severe respiratory 
illness as SARS-CoV2 does, severe acute respiratory syndrome coronavirus (SARS-CoV) and 
the Middle East respiratory syndrome coronavirus (MERS-CoV) with a nucleotide identity 
to SARS-CoV2 of 79 and 50 % respectively (11), also tend to be more severe and fatal in 
men than in women (12–15). 
Besides lifestyle factors, the sex-specific difference in coronavirus susceptibility and 
disease outcomes is caused by sex differences in the immune response, both innate and 
adaptive (16). One of the explanations for this sex difference in COVID-19 susceptibility is 
chromosomal: X chromosome contains more immune-related genes than the Y chromo-
some, and activation of these genes leads to stronger female immune response to viral 
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infection (7,17,18). Another explanation is hormonal: hor-
mones, such as estrogen, which females produce in larger 
quantities than males, help to defend against coronaviruses 
like MERS-CoV, SARS-CoV and SARS-CoV2. There are various 
possible explanations of estrogen protective action mecha-
nism (19–24). Among the effects of estrogen in the immune 
defence, there is an influence on adaptive immunity fighters, 
T- and B-cells, by impairing negative selection of high affinity 
auto-reactive B cells, modulating B cell function and leading 
to Th2 response (25), and induction of T cell homing by en-
hancing the expression of CCR5, a homing marker (26). An 
experiment performed with mice infected with mouse-
-adapted SARS-CoV MA15 (27) showed that the male mice 
were more susceptible to the SARS infection than females, 
and that the female mice that had their estrogen-producing 
ovaries removed or were treated with an estrogen-receptor 
blocker had higher fatality rates than those with normal 
estro gen function. The sex-specific differences were inde-
pendent of T and B cell responses. Therefore, these results 
suggest that estrogen receptor (ER) signalling in females sup-
pressed the accumulation and function of inflammatory 
monocyte macrophages in the lungs and/or directly sup-
pressed SARS-CoV replication via effects on cellular metabo-
lism. 
Besides acting on ER signalling as a mechanism of confer-
ring strong positive effect on disease outcomes and fatality 
rate (25), we considered the idea that the estrogen might act 
directly on the virus. We hypothesized that the estrogen mol-
ecule might bind on the virus surface and thus reduce its in-
fectivity. Since spike (S) protein is the major surface protein 
the SARS-CoV2 employs to bind to the human receptor and 
initiate fusion with the host cell (26–29), we wondered if there 
was any theoretical possibility that estrogen could bind to 
this protein. If this were indeed the case, then estrogen and 
estrogen-like molecules might have a therapeutic effect. To 
get some insight into these questions, we first performed 
protein BLAST to determine if there was any similarity be-
tween SARS-CoV2 S protein and the human ER β sequences. 
Although these two proteins originate from different species 
and differ greatly in their overall size, a sequence similarity 
was found in regions which correspond to the estrogen bind-
ing site of the human ER β. We further explored the spatial 
structure of potential estrogen binding site on S protein us-
ing PyMol software and again found substantial similarities 
with the 3D structure of binding site on the human ER β. 
MATERIALS AND METHODS 
Protein sequences and 3D structures
The following protein sequences were downloaded from 
NCBI (30): human ER β sequence (UniProtKB/Swiss-Prot: 
Q92731.2), human androgen (dihydrotestosterone) receptor 
(UniProtKB/Swiss-Prot: P10275.3), SARS-CoV2 surface glyco-
protein (NCBI reference sequence: YP_009724390.1) and SARS 
CoV Urbani spike protein (GenBank: AYV99817.1). The 
following 3D structures were downloaded from RCSB Protein 
Data Bank (31): crystal structure of ER β bound to estradiol 
(PDB ID: 5TOA (32)), crystal structure of human androgen re-
ceptor ligand-binding domain in complex with dihydrotes-
tosterone (PDB ID: 2AMA (33)) and prefusion 2019-nCoV spike 
glycoprotein with a single receptor-binding domain up (PDB 
ID: 6VSB (29)). 
Bioinformatic tools
Protein sequence alignment and analysis were performed 
using protein BLAST (34) and the HHpred server for remote 
protein homology detection and structure prediction 
(https://toolkit.tuebingen.mpg.de/tools/hhpred (35)). In all 
cases, standard algorithm parameters were used (36,37). For 
3D protein structure, visualization the PyMOL software was 
used (38). 
RESULTS AND DISCUSSION
To assess whether there could be any possibilities for the 
S protein of SARS-CoV2 to contain a site that might bind es-
trogen, we used protein BLAST to compare its sequence with 
human ER β. We found three regions of similarity. The two 
more significant were: a region of 19 amino acids starting 
from amino acid 319 of the ER β and amino acid 817 of S pro-
tein with 73 % positives without gaps (e-value 2.5) and a re-
gion of 14 amino acids starting from amino acid 385 of the ER 
β and amino acid 236 of S protein with 64 % positives without 
gaps (e-value 3.2). Although the e-values were relatively high, 
we found it interesting that both of these two regions are an-
notated in NCBI as part of the ligand-binding domain of the 
estrogen receptor. 
Furthermore, we visualized the 3D structure of the SARS-
-CoV2 S protein, using PyMOL software (38), and compared it 
to the 3D structure of ER β to check whether the regions of S 
protein carrying either the 19 or 14 amino acid alignments 
found by BLAST bear any spatial resemblance to the estrogen 
binding site of ER β and thus could constitute a potential es-
trogen binding site on the S protein. According to the 3D 
structure analysis, the 19 amino acid region (319F to 337E) ap-
pears to play an important role in the ligand-binding domain 
on the ER β (Fig. 1a) since it protrudes into the active site with 
the methionine 336M as the closest amino acid to the estra-
diol (a major form of estrogen in women of reproductive age) 
when bound. The residue 336M is less than 5 Å apart from the 
estradiol molecule (Fig. 1b). Therefore, it is reasonable to as-
sume that the terminal part of the 19 amino acid alignment 
constitutes a part of an active site on ER β. Residues involved 
in ligand-binding on ER β are glutamate 305E situated on the 
first alpha helix and the glycine 472G and histidine 475H situ-
ated on the second alpha helix, which form three polar bonds 
with estradiol (Fig. 1c). 
In the SARS-CoV2 S protein, the 19 amino acid alignment 
begins with phenylalanine 817F. In the corresponding 3D 
structure obtained by electron micrograph (29) residues 817F 
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through 828L can be found. Unfortunately, the structure con-
tains a brakeage of protein chain between the residues 811 
and 815 as well as 828 and 853 resulting in separation of this 
part of the molecule. Moreover, the protein chain breakage 
visible in the 3D structure of SARS-CoV2 S protein is present 
at the approximately same site in the SARS-CoV Urbani 3D 
structure (the related coronavirus causing SARS pandemic in 
2003), indicating that this particular site is sensitive to sample 
preparation and manipulation. However, the separated alpha 
helix is located near the breakage site, indicating that it has 
not moved considerably from its native position (Fig. 2). In-
stead of methionine 336M present in the analyzed 19 amino 
acid region on ER β, the corresponding region on S protein 
contains an analogue nonpolar residue isoleucine 834I scored 
as positive by BLAST. Although the exact position of 834I in 
the available model of S protein cannot be observed due to 
the protein chain breakage, it can be positioned in space 
based on the surrounding residues. We then tried to identify 
the amino acids that might be close in space to the 834I and 
could form polar bonds with estradiol molecule. Using BLAST, 
we identified a region of S protein (residues 1045 to 1052), 
which aligns with the region of ER β spanning residues 471 to 
479 with 66 % of them scored as positives, and which contains 
two key residues for estradiol binding on ER β – 472G and 
475H. The main difference is that on the S protein the glycine 
and histidine are separated by one amino acid (Y), while two 
residues in between are present on the ER β (M and E). To find 
the potential analogue of the third amino acid responsible 
for estradiol binding on ER β (305E), we used the HHpred serv-
er (35). The region spanning residues 289 to 310 of ER β (con-
taining 305E) was compared against the entire sequence of 
S protein. The analysis resulted in region spanning residues 
from 1013 to 1033 of S protein identified as similar with two 
gaps introduced to achieve the alignment of 305E with its po-
tential analogue on the S protein – the glutamate at position 
1031.
Fig. 1. The 3D structure of: a) human estrogen receptor β in the vicinity of 19 amino acid sequence alignment with the S protein spanning residues 
from F319 do E337 (orange) with estradiol (magenta) bound to the active site, b) the alignment ends with M336 protruding into the active site 
and being less than 5 Å from the estradiol molecule, and c) the active site seen from different perspective offers better view of other surrounding 
residues likely involved in binding (yellow) and the three residues (E305, G472 and H475, marked red) which can form polar bonds with estradiol
Fig. 2. The 3D structure of S protein in the vicinity of potential es-
trogen binding site. The 19 amino acid sequence alignment with the 
region on ER β is shown in orange. Residues R815 and L828 are sites of 
protein chain breakage. Amino acids possibly involved in polar bind-
ing of estrogen in the potential active sites (E1031, G1046 and H1048) 
are marked red, while other residues surrounding the potential bind-
ing site are shown in yellow
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Finally, using PyMol (38), we visualized the spatial position 
of three amino acids, which can form polar bonds with the 
ligand (1046G, 1048H and 1031E) on the 3D structure of S pro-
tein and compared this site to the active site for estradiol 
binding on ER β. Histidine residue 1048H on the S protein was 
rotated in space around alpha C atom to face towards the 
1031E, which is likely to occur in the case of estradiol binding. 
The three key amino acids on the ER β responsible for polar 
binding of estradiol form a triangle with the length of its sides 
being 4.7, 12.8 and 14.8 Å (Fig. 3a). On the S protein the three 
analogous amino acids form a triangle with sides 4.6, 14.8 and 
11.3 Å long (Fig. 3b). In other words, the dimensions of the 
space between the residues capable of forming polar bonds 
with estradiol in ER β and the analyzed site on S protein are 
curiously similar, with the main difference being that the lon-
gest side of the triangle in the active site of ER β is between 
histidine and glutamate and of the S protein between glycine 
and glutamate. Moreover, besides the three residues with the 
potential of forming polar bonds with estradiol, a number of 
other residues surrounding the potential binding site on S 
protein are identical or similar in their chemical properties to 
that present in the ER β active site (Figs. 3c and 3d). 
As a control, sequences and 3D structures of S protein and 
human androgen receptor were compared using the same 
methodology as described above. Although testosterone 
and estrogen are highly similar molecules and the estrogen 
and testosterone receptors share regions of notable similar-
ity in the ligand-binding domain, we did not find sequence 
alignments of S protein with the androgen receptor that in-
clude all three key residues for testosterone binding (R, T and 
N), nor could we identify a site in the 3D structure of S protein 
that would share significant resemblance to the testosterone 
binding site (data not shown). 
Taken together, our analyses suggest that SARS-CoV2 S 
protein features a potential estrogen binding site. Under-
standably, whether or not the estradiol molecule actually can 
bind to the potential site – and if it does bind, how it affects 
the S protein and the infectivity of the virus can be estab-
lished only experimentally. The strong positive effect of es-
trogen on disease outcome and fatality rate was experimen-
tally shown in mice using mouse-adapted SARS-CoV MA15 
and the effect was explained by estrogen receptor signalling 
(27). The entire S protein of mouse-adapted strain differs in 
only one amino acid from the SARS-CoV, the human virus 
causing the SARS 2003 epidemic (27). Thus, we wondered if 
SARS-CoV, which is closely related to SARS-CoV2, also fea-
tures a potential estrogen binding site and whether it is con-
ceivable that at least to an extent the positive effect of 
Fig. 3. Comparison of estrogen binding site of ER β and potential estrogen binding site found on S protein of SARS-CoV2. Amino acids E, G and 
H capable of forming polar bonds with estrogen are depicted red: a) sides of the triangle between E, G and H residues are 4.7, 12.8 and 14.8 Å on 
ER β, and b) 4.6, 14.8 i 11.3 Å on S protein, c) identical (red and purple) and similar (yellow) residues surrounding the estrogen binding site of ER β 
compared with d) potential estrogen binding site on SARS-CoV2 S protein 
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estrogen observed in these experiments might be due to the 
S protein binding estrogen. The BLAST analysis revealed that 
in the region 800–1273, which includes the potential estro-
gen binding site, the two S proteins are 93 % identical (with 
97 % amino acids scored as positives without gaps). The 3D 
structure of SARS-CoV also presented the same conformation 
in the investigated region with the potential estrogen bind-
ing site present (data not shown). 
Moreover, the entire region of SARS-Cov2 S protein rang-
ing from residue 662 to 1270 is a conserved S2 domain be-
longing to the coronavirus S2 superfamily. After transcription, 
the S protein is cleaved to S1 and S2 subunits. The S1 is re-
sponsible for binding to the host receptor, while the S2 sub-
unit contains machinery for fusion with the host cell which 
consists of several distinct regions: the fusion peptide, heptad 
repeats 1 and 2 (HR1 and HR2) and transmembrane domain 
(39). The potential estrogen binding site identified in this 
work lies in the region carrying a linker between the two hep-
tad repeats (40). A BLAST analysis of SARS-CoV2 S protein re-
gion 1025 to 1055 against S proteins of 20 randomly chosen 
species across the Coronaviridae family showed that this site 
is conserved, with the three amino acids (E, G and H) likely 
capable of forming polar bonds with estradiol together with 
some of the surrounding amino acids being present across 
the family (Fig. 4). Given the similarities of this region to the 
ER β, it is possible that an ancestral viral species at some point 
in time integrated a section of an ER from its host (41). How-
ever, it seems that this section might have taken on an impor-
tant role in the coronavirus infectivity as a part S2 domain, 
perhaps being involved in host-virus membrane fusion by 
binding of other molecules featuring four rings, such as cho-
lesterol. Thus, binding of estrogen might compete with the 
natural ligand for this site or cause conformational changes 
leading to reduced function of S2 domain and diminished in-
fectivity.
Given the differences in COVID19 disease outcomes and 
fatality rate between men and women, the usage of estra-
diol to reduce severity of COVID19 infection is currently being 
tested in a phase II clinical trial in Stony Brook University Hos-
pital, New York, NY, USA (https://clinicaltrials.gov/ct2/show/
NCT04359329). The positive and suspected to be positive pa-
tients are given estradiol patches delivering 100 μg/day of 
estradiol for 7 days and rates of hospitalization, transfer to 
intensive care unit, intubation and death are being moni-
tored during the 30-day time frame and compared to the 
non-treated control. The study recruits men over the age of 
18 and women over the age of 55. Hopefully, although pre-
liminary, the results presented in this work will inspire more 
researchers into investigating estrogen and estrogen-like 
molecules for treating COVID-19 since using different drugs, 
doses and methods of delivery could all affect the final result. 
CONCLUSIONS
In this work, we identified a conserved potential estrogen 
binding site on SARS-CoV2 surface glycoprotein (S protein). 
This result could offer additional explanation of the better 
disease outcomes for COVID19 positive women than men, as 
well as of the strong protective effect of estrogen in experi-
mental animals. Most importantly, this result could prompt 
other researchers to experimentally prove whether or not the 
estrogen can indeed bind to the S protein and what effect 
would that confer on the infectivity of the virus. Hopefully, 
estrogen or estrogen-like molecule might be used to treat 
SARS-CoV2 infection or alleviate symptoms. 
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